Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV ( Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021.
Professor Alan Stitt, Ph.D., CSO at Oxurion NV comments: “We are happy to present these scientific findings at the ARVO 2021 annual meeting. A deep understanding of the cellular and molecular mechanisms that underpin retinal disease and the use relevant preclinical models are instrumental for developing novel therapeutics. We are happy to share our insights with the global vision research community and mutually strengthen knowledge in the field.”
The details of the presentation are as follows:
Title: The Mouse Sodium Iodate Model Exhibits Acute Retinal Inflammation
Authors: Karen Beets, Michaël Porcu, Tjing-Tjing Hu, Jean Feyen ( Oxurion NV, Leuven, Belgium)
Date and time: May 1st, 3:15 PM - 5:00 PM BST
The data presented supports the use of the NaIO3 model for the investigation of age-related macular degeneration (AMD) hallmarks, a disease area where Oxurion has a number of on-going preclinical research activities.
The poster will be available to conference attendees via the conference website. The abstract is available here.
For further information please contact:
| Oxurion NV|
Global Head of Investor Relations
& Corporate Communications
Tel: +32 478 33 56 32
| EU |
Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi/Frazer Hall
Tel: +44 20 7638 9571
Westwicke, an ICR Company
Tel: +1 617 835 9304
Oxurion ( Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders. The company' focus is on diabetic macular edema (DME), the primary cause of vision loss in diabetic patients worldwide, as well wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders, with an initial focus on DME, based on the successful development of its two novel therapeutics:
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.